---
title: Biotransformation & In Vivo CQA Analysis | CBS
description: "Characterization of biologics, multispecifics and ADCs in serum and other matrices by immunocapture and HRMS: biotransformation, in vivo CQAs and PK/PD investigation."
---

![Logo\_CBS-横版-原色(RGB)](https://www.crystalbiosolutions.com/hs-fs/hubfs/Logo_CBS-%E6%A8%AA%E7%89%88-%E5%8E%9F%E8%89%B2(RGB)-2.png?width=330&height=150&name=Logo_CBS-%E6%A8%AA%E7%89%88-%E5%8E%9F%E8%89%B2(RGB)-2.png)

- Bioanalysis & Biomarkers 
    - [All Bioanalysis & Biomarker Services](https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers)
    - [PK Assays for Biologics & ADCs](https://www.crystalbiosolutions.com/services/pk-bioanalysis)
    - [NAb & ADA Immunogenicity Assays](https://www.crystalbiosolutions.com/ada-and-nab-testing-in-biologics-pk-efficacy-and-regulatory-risk)
    - [Receptor Occupancy Assays](https://www.crystalbiosolutions.com/services/receptor-occupancy-assays)
- Biologics CMC Analytical 
    - [All Biologics CMC Analytical Services](https://www.crystalbiosolutions.com/characterization-cmc-analytical)
    - [Developability Assessment](https://www.crystalbiosolutions.com/services/biologics-developability-assessment)
    - [Extended Characterization by HRMS](https://www.crystalbiosolutions.com/services/biologics-extended-characterization-hrms)
    - [Biotransformation & In Vivo CQA](https://www.crystalbiosolutions.com/services/biotransformation-in-vivo-cqa)
- [Clinical Pharmacology](https://www.crystalbiosolutions.com/services/clinical-pharmacology)
- Solutions 
    - [ADC Programs](https://www.crystalbiosolutions.com/antibody-drug-conjugates-adc)
    - [Regulatory Affairs Support](https://www.crystalbiosolutions.com/services/regulatory-affairs-biologics-adc-cgt)
    - [Clinical Support](https://www.crystalbiosolutions.com/clinical-research-services)

- [Resources](https://www.crystalbiosolutions.com/news-and-events)
- [About Us](https://www.crystalbiosolutions.com/about-us)
- [Request a Proposal](https://www.crystalbiosolutions.com/contact-us)

![Analytical laboratory with mass spectrometry instruments for biotransformation analysis of biologics](https://www.crystalbiosolutions.com/hs-fs/hubfs/website-assets/cbs-home-cmc-analytical-lab-instruments.jpg?width=960&height=640&name=cbs-home-cmc-analytical-lab-instruments.jpg)

# Biotransformation and In Vivo CQA Analysis

A biologic can change after dosing through deamidation, oxidation, clipping or, for ADCs, deconjugation. Crystal Bio Solutions, part of Crystal Group, characterizes drugs directly in serum and other biological matrices, using immunocapture (IP pulldown) followed by high-resolution mass spectrometry in our biologics CMC analytical laboratory in Natick, Massachusetts. The results show which attributes change in vivo and help explain PK and PD data.

[![Let's talk](https://hubspot-no-cache-eu1-prod.s3.amazonaws.com/cta/default/146565877/interactive-264126601418.png)](https://www.crystalbiosolutions.com/hs/cta/wi/redirect?encryptedPayload=AVxigLKjew5Hk7t5dnin9DDs%2BYVnpOKLhBEOgOytA31aWxf65R%2BRR7evobKegVpbcRNxYAolF%2BnjfiI7Qggv7J0VD%2Fwvvw6Zq2sqZhwWDtqLozufQCfOmjxoayMQ5I5c%2F8kf0Sit2Kf%2F1nzvgYIbZq9gkqQ9ta26MM%2BuQIoG7q6JqkoMeDpNj%2FwDNRP%2F%2Fbx%2ByJnjkaB43SaSN6wFwLm%2BlVwO7rXhdGly&webInteractiveContentId=264126601418&portalId=146565877&hsLang=en)

![CBS orange-blue banner-1](https://www.crystalbiosolutions.com/hs-fs/hubfs/CBS%20orange-blue%20banner-1.png?width=2000&height=21&name=CBS%20orange-blue%20banner-1.png "CBS orange-blue banner-1")

Immunocapture and HRMS Specific pulldown of the drug from serum or tissue matrix, followed by intact, subunit or peptide-level HRMS analysis. Matrix Stability In vitro serum and matrix stability studies that show how quickly attributes change and which modifications form. In Vivo CQA Analysis Characterization of drug recovered from animal or human study samples to identify attributes that change after dosing. Complex Formats Biotransformation of bispecific and trispecific antibodies, ADCs and other complex proteins, including chain-level and DAR changes. PK/PD Problem Investigation Investigation of unexpected PK or PD results, such as faster clearance or loss of activity, by linking them to structural changes. Biomarker Characterization Mass spectrometry characterization of protein biomarkers to support assay development and interpretation.

![CBS orange banner-1](https://www.crystalbiosolutions.com/hs-fs/hubfs/website-assets/CBS%20orange%20banner-1.png?width=2000&height=24&name=CBS%20orange%20banner-1.png "CBS orange banner-1")

![Crystal Bio Solutions biologics CMC analytical laboratory in Natick, Massachusetts](https://www.crystalbiosolutions.com/hs-fs/hubfs/CBS-lab/IMG_8892.jpeg?width=640&height=480&name=IMG_8892.jpeg) Why In Vivo Attributes Matter Release methods describe the drug as manufactured. After dosing, the molecule is exposed to body temperature, pH and enzymes for days or weeks. Changes at that stage can alter potency, clearance or immunogenicity.

- They help define which attributes are truly critical
- They explain differences between PK assay formats, for example total antibody versus conjugated drug
- They support comparability arguments when a process change affects a labile site

Results are coordinated with PK bioanalysis in our Pleasanton laboratory.

**Related reading:** [Critical quality attribute D0 impact in ADC modality](https://www.crystalbiosolutions.com/news-and-events/critical-quality-attribute-d0-impact-in-adc-modality?hsLang=en)

## Related Services

Biologics CMC Analytical Characterization, CMC analytical strategy and gap analysis for biologics. Extended Characterization by HRMS Intact mass, peptide mapping, PTMs, disulfides, glycans and charge variants. ADC Programs DAR, conjugation, payload stability and ADC bioanalysis. PK Assays for Biologics and ADCs Total antibody, conjugated drug and free payload assays.

## Frequently Asked Questions

 

### What is biotransformation of a biologic?

Biotransformation is the set of changes a drug undergoes in the body, such as deamidation, oxidation, clipping, glycan changes or, for ADCs, loss or exchange of payload. These changes can affect activity, clearance and immunogenicity.

 

### What is an in vivo critical quality attribute?

It is a quality attribute that changes after dosing in a way that can affect safety or efficacy. Measuring attributes in circulating drug shows which sites are labile in vivo, which can differ from what release and stability data suggest.

 

### How is a drug characterized in serum?

The drug is first captured from the sample with a specific reagent, for example its target or an anti-drug antibody (immunocapture or IP pulldown), to separate it from abundant serum proteins. The captured drug is then analyzed by high-resolution mass spectrometry at the intact, subunit or peptide level.

 

### Why is this important for ADCs and multispecifics?

ADCs can lose payload or undergo linker changes in circulation, and multispecifics can show chain-specific clipping or modifications. Characterizing them in matrix explains differences between PK analytes and supports design and comparability decisions.

 

### When should a biotransformation study be considered?

When PK results are unexpected, when total and active drug measurements diverge, when a molecule has known labile sites, or when a process change affects attributes that may matter in vivo.

 

### Where is this work performed?

Biotransformation studies are performed in the CBS biologics CMC analytical laboratory in Natick, Massachusetts, coordinated with PK bioanalysis in the CBS GLP- and GCLP-compliant laboratory in Pleasanton, California.

 

## Have a Question?

Connect with our experts and get started on your project today.

[![Free Consultation](https://hubspot-no-cache-eu1-prod.s3.amazonaws.com/cta/default/146565877/interactive-270508115133.png)](https://www.crystalbiosolutions.com/hs/cta/wi/redirect?encryptedPayload=AVxigLLRQWGCqlFXzr8fB3iVKFF64L8W5zcRWTy5LY8E6DMX%2BMQy2A4gyL9O4v2tIsFUBZSBl%2BRgb%2BFgKR4K6bD%2FA9jXR3covbmW9yP7hmvHNtDKOxUBFXFLWXMzldllsNBIODxtcNpgkFBWDabLjEGA37blESl2CheOO6PB5rQkMzOn1Pk%2FGYLswELQRw22ToxUBSw7y4rmJ%2FrCxJ%2FsjnzbpaO8Tujq&webInteractiveContentId=270508115133&portalId=146565877&hsLang=en)

![Logo\_CBS-竖版-反白](https://www.crystalbiosolutions.com/hubfs/Logo_CBS-%E7%AB%96%E7%89%88-%E5%8F%8D%E7%99%BD.png)

- [Our Services](https://www.crystalbiosolutions.com) 
    - [Bioanalysis and Biomarker](https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers)
    - [CMC Analytical](https://www.crystalbiosolutions.com/characterization-cmc-analytical)
    - [Clinical Pharmacology](https://www.crystalbiosolutions.com/services/clinical-pharmacology)
    - [Regulatory Affairs](https://www.crystalbiosolutions.com/services/regulatory-affairs-biologics-adc-cgt)
    - [Clinical Support](https://www.crystalbiosolutions.com/clinical-research-services)
- [Information](https://www.crystalbiosolutions.com/news-and-events) 
    - [About us](https://www.crystalbiosolutions.com/about-us)
    - [Quality & Compliance](https://www.crystalbiosolutions.com/quality-and-compliance)
    - [Resources](https://www.crystalbiosolutions.com/news-and-events)
    - [News & Events](https://www.crystalbiosolutions.com/news-and-events)
    - [Careers](https://www.crystalbiosolutions.com/careers-at-crystal-bio-solutions)
- [Contact](https://www.crystalbiosolutions.com/contact-us) 
    - [Email \>](mailto:cbs_bd@crystalpharmatech.com)
    - [Contact Form](https://www.crystalbiosolutions.com/contact-us)
    - [Our Locations](https://www.crystalbiosolutions.com/locations)
    - [Crystal Group \>](https://www.crystalpharmatech.com/) 
          - [Crystal Pharmatech](https://www.crystalpharmatech.com/)
          - [Crystal NAX](https://www.crystalnax.com/)

<https://www.linkedin.com/company/crystal-bio-solutions/> <https://x.com/crystalbiosol> <https://www.facebook.com/people/Crystal-Bio-Solutions/61579857412775/> <https://www.instagram.com/crystalbiosol/> <https://bsky.app/profile/crystalbiosol.bsky.social>

- [Privacy Policy](https://www.crystalbiosolutions.com/policies/privacy-policy)
- [Terms of Service](https://www.crystalbiosolutions.com/policies/terms-of-service)

Copyright © 2026 Crystal Bio Solutions, All rights reserved

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://www.crystalbiosolutions.com/#organization",
  "@type" : "Organization",
  "alternateName" : "CBS",
  "contactPoint" : [ {
    "@type" : "ContactPoint",
    "contactType" : "sales",
    "email" : "cbs_bd@crystalpharmatech.com",
    "url" : "https://www.crystalbiosolutions.com/contact-us"
  } ],
  "logo" : "https://www.crystalbiosolutions.com/hs-fs/hubfs/CBS%20VI%20v2/CBS%20Logo.png",
  "name" : "Crystal Bio Solutions",
  "parentOrganization" : {
    "@type" : "Organization",
    "name" : "Crystal Group",
    "url" : "https://www.crystalpharmatech.com/"
  },
  "sameAs" : [ "https://www.linkedin.com/company/crystal-bio-solutions/", "https://x.com/crystalbiosol", "https://www.facebook.com/people/Crystal-Bio-Solutions/61579857412775/", "https://www.instagram.com/crystalbiosol/", "https://bsky.app/profile/crystalbiosol.bsky.social" ],
  "url" : "https://www.crystalbiosolutions.com/"
}
```

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://www.crystalbiosolutions.com/#website",
  "@type" : "WebSite",
  "inLanguage" : "en",
  "name" : "Crystal Bio Solutions",
  "publisher" : {
    "@id" : "https://www.crystalbiosolutions.com/#organization"
  },
  "url" : "https://www.crystalbiosolutions.com/"
}
```

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://www.crystalbiosolutions.com/services/biotransformation-in-vivo-cqa/#webpage",
  "@type" : "WebPage",
  "about" : {
    "@id" : "https://www.crystalbiosolutions.com/services/biotransformation-in-vivo-cqa/#service"
  },
  "breadcrumb" : {
    "@id" : "https://www.crystalbiosolutions.com/services/biotransformation-in-vivo-cqa/#breadcrumb"
  },
  "description" : "Characterization of biologics, multispecifics and ADCs in serum and other matrices by immunocapture and HRMS: biotransformation, in vivo CQAs and PK/PD investigation.",
  "inLanguage" : "en",
  "isPartOf" : {
    "@id" : "https://www.crystalbiosolutions.com/#website"
  },
  "name" : "Biotransformation & In Vivo CQA Analysis | CBS",
  "url" : "https://www.crystalbiosolutions.com/services/biotransformation-in-vivo-cqa"
}
```

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://www.crystalbiosolutions.com/services/biotransformation-in-vivo-cqa/#service",
  "@type" : "Service",
  "areaServed" : "Worldwide",
  "description" : "Characterization of biologics in serum and other biological matrices by immunocapture and high-resolution mass spectrometry, including matrix stability, in vivo CQA analysis, biotransformation of multispecifics and ADCs, and PK/PD investigation.",
  "hasOfferCatalog" : {
    "@type" : "OfferCatalog",
    "itemListElement" : [ {
      "@type" : "Offer",
      "itemOffered" : {
        "@type" : "Service",
        "name" : "Immunocapture (IP pulldown) with HRMS"
      }
    }, {
      "@type" : "Offer",
      "itemOffered" : {
        "@type" : "Service",
        "name" : "Serum and matrix stability studies"
      }
    }, {
      "@type" : "Offer",
      "itemOffered" : {
        "@type" : "Service",
        "name" : "In vivo CQA analysis"
      }
    }, {
      "@type" : "Offer",
      "itemOffered" : {
        "@type" : "Service",
        "name" : "Biotransformation of multispecifics and ADCs"
      }
    }, {
      "@type" : "Offer",
      "itemOffered" : {
        "@type" : "Service",
        "name" : "PK/PD problem investigation"
      }
    }, {
      "@type" : "Offer",
      "itemOffered" : {
        "@type" : "Service",
        "name" : "Protein biomarker characterization"
      }
    } ],
    "name" : "Biotransformation and In Vivo CQA Analysis"
  },
  "name" : "Biotransformation and In Vivo CQA Analysis",
  "provider" : {
    "@id" : "https://www.crystalbiosolutions.com/#organization"
  },
  "url" : "https://www.crystalbiosolutions.com/services/biotransformation-in-vivo-cqa"
}
```

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://www.crystalbiosolutions.com/services/biotransformation-in-vivo-cqa/#breadcrumb",
  "@type" : "BreadcrumbList",
  "itemListElement" : [ {
    "@type" : "ListItem",
    "item" : "https://www.crystalbiosolutions.com/",
    "name" : "Home",
    "position" : 1
  }, {
    "@type" : "ListItem",
    "item" : "https://www.crystalbiosolutions.com/characterization-cmc-analytical",
    "name" : "Biologics CMC Analytical",
    "position" : 2
  }, {
    "@type" : "ListItem",
    "item" : "https://www.crystalbiosolutions.com/services/biotransformation-in-vivo-cqa",
    "name" : "Biotransformation and In Vivo CQA",
    "position" : 3
  } ]
}
```

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://www.crystalbiosolutions.com/services/biotransformation-in-vivo-cqa/#faq",
  "@type" : "FAQPage",
  "mainEntity" : [ {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "Biotransformation is the set of changes a drug undergoes in the body, such as deamidation, oxidation, clipping, glycan changes or, for ADCs, loss or exchange of payload. These changes can affect activity, clearance and immunogenicity."
    },
    "name" : "What is biotransformation of a biologic?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "It is a quality attribute that changes after dosing in a way that can affect safety or efficacy. Measuring attributes in circulating drug shows which sites are labile in vivo, which can differ from what release and stability data suggest."
    },
    "name" : "What is an in vivo critical quality attribute?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "The drug is first captured from the sample with a specific reagent, for example its target or an anti-drug antibody (immunocapture or IP pulldown), to separate it from abundant serum proteins. The captured drug is then analyzed by high-resolution mass spectrometry at the intact, subunit or peptide level."
    },
    "name" : "How is a drug characterized in serum?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "ADCs can lose payload or undergo linker changes in circulation, and multispecifics can show chain-specific clipping or modifications. Characterizing them in matrix explains differences between PK analytes and supports design and comparability decisions."
    },
    "name" : "Why is this important for ADCs and multispecifics?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "When PK results are unexpected, when total and active drug measurements diverge, when a molecule has known labile sites, or when a process change affects attributes that may matter in vivo."
    },
    "name" : "When should a biotransformation study be considered?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "Biotransformation studies are performed in the CBS biologics CMC analytical laboratory in Natick, Massachusetts, coordinated with PK bioanalysis in the CBS GLP- and GCLP-compliant laboratory in Pleasanton, California."
    },
    "name" : "Where is this work performed?"
  } ]
}
```